Aimei Health Technology Co., Ltd. (AFJK) Form 10-Q — Aug 13, 2026
Aimei Health Technology Co., Ltd. (Nasdaq: AFJK), a Cayman Islands healthcare-focused blank check company, disclosed in its June 30, 2026 Form 10-Q that it delivered United Hydrogen a notice of termination of the Business Combination Agreement on July 7, 2026, after the China Securities Regulatory Commission had not granted required approvals. The SPAC is now without a deal and says it continues to evaluate other business combination opportunities. For Q2 2026 the company reported a net loss of $83,144, versus net income of $424,970 in the prior-year quarter, as trust interest income fell to $109,204 and general and administrative costs rose to $192,348.
Key figures
- Total Assets
- 12532359
- Cash Position
- 1466
- Shares Outstanding
- 3166332
- Q2 2026 ga costs
- 192348
- Total liabilities
- 4528684
- Q2 2025 net income
- 424970
- Due to related company
- 1129651
- Fy2025 redeemed shares
- 5859668
- Six month 2026 ga costs
- 254332
- Working capital deficit
- 3794718
- Fy2025 share redemptions
- 65330000
- Deferred underwriting fee
- 690000
- Six month 2025 net income
- 609632
- Ipo gross proceeds dec 2023
- 69000000
- Business combination deadline
- December 6, 2026
- Redeemable shares outstanding
- 1040332
- Subsequent extension loans total
- 68662
- Trust account balance june 30 2026
- 12488393
- Six month 2026 trust interest income
- 216628
- Extension loans related party outstanding
- 2195717
Price after filing
Close on the filing date to close N calendar days later (from $12.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.